DMAA (also known as geranamine, methylhexanamine, dimethylamylamine, 1,3-dimethylamylamine) is a natural CNS stimulant that was first synthesized and patented in 1944 by pharmaceutical company Eli Lilly. The substance was originally patented as a nasal decongestant. Geranamine is increasingly used as main ingredient in energizer, fitness supplements and weight-loss products.
The stimulant effects of geranamine on the central nervous system (CNS) are said to be less than amphetamine and ephedra. Effects are dose-dependent and include euphoria, elevated mood, intense energy, adrenaline rush, mental clarity and increased confidence.
IUPAC Name: 4-methylhexan-2-amine
CAS Number: 105-41-9
Molar Mass: 115.22 g/mol
The chemical structure shows resemblances to that of amphetamines and ephedrine.
The name ‘Geranamine’ is actually a trademark name, registered by Proviant Technologies. DMAA is a naturally-occurring constituute of the geranium plant (Pelargonium graveolens). However, this is less than 1%, and most DMAA on the market is produced synthetically.
Geranamine is currently legal in most countries. Because the compound is a natural constituent of geraniums and is unscheduled it can be sold as a dietary supplement under current FDA laws.
In 2010, the World Anti-Doping Agency (WADA) added geranamine to the list of banned performance enhancing substances.